Network pharmacology: the next paradigm in drug discovery
- PMID: 18936753
- DOI: 10.1038/nchembio.118
Network pharmacology: the next paradigm in drug discovery
Abstract
The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets. However, many effective drugs act via modulation of multiple proteins rather than single targets. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This new appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development--efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets. However, the rational design of polypharmacology faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties. Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacology.
Similar articles
-
Druggable targets and targeted drugs: enhancing the development of new therapeutics.Pharmacology. 2008;82(4):239-44. doi: 10.1159/000157624. Epub 2008 Sep 19. Pharmacology. 2008. PMID: 18802381 Review.
-
PubChem as a source of polypharmacology.J Chem Inf Model. 2009 Sep;49(9):2044-55. doi: 10.1021/ci9001876. J Chem Inf Model. 2009. PMID: 19708682
-
Fragments, network biology and designing multiple ligands.Drug Discov Today. 2007 Feb;12(3-4):156-60. doi: 10.1016/j.drudis.2006.12.006. Epub 2006 Dec 14. Drug Discov Today. 2007. PMID: 17275736 Review.
-
Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective.Curr Pharm Des. 2016;22(21):3171-81. doi: 10.2174/1381612822666160224142812. Curr Pharm Des. 2016. PMID: 26907941 Review.
-
Can we rationally design promiscuous drugs?Curr Opin Struct Biol. 2006 Feb;16(1):127-36. doi: 10.1016/j.sbi.2006.01.013. Epub 2006 Jan 25. Curr Opin Struct Biol. 2006. PMID: 16442279 Review.
Cited by
-
Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors Based on the Pyridyl-Pyridazine Moiety for the Potential Treatment of Alzheimer's Disease.Pharmaceuticals (Basel). 2024 Oct 21;17(10):1407. doi: 10.3390/ph17101407. Pharmaceuticals (Basel). 2024. PMID: 39459045 Free PMC article.
-
Exploiting genomic knowledge in optimising molecular breeding programmes: algorithms from evolutionary computing.PLoS One. 2012;7(11):e48862. doi: 10.1371/journal.pone.0048862. Epub 2012 Nov 21. PLoS One. 2012. PMID: 23185279 Free PMC article.
-
Investigating the effects and mechanisms of Erchen Decoction in the treatment of colorectal cancer by network pharmacology and experimental validation.Front Pharmacol. 2022 Oct 13;13:1000639. doi: 10.3389/fphar.2022.1000639. eCollection 2022. Front Pharmacol. 2022. PMID: 36313338 Free PMC article.
-
Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications.Int J Mol Sci. 2022 Nov 10;23(22):13869. doi: 10.3390/ijms232213869. Int J Mol Sci. 2022. PMID: 36430344 Free PMC article.
-
Network Pharmacology of Adaptogens in the Assessment of Their Pleiotropic Therapeutic Activity.Pharmaceuticals (Basel). 2022 Aug 25;15(9):1051. doi: 10.3390/ph15091051. Pharmaceuticals (Basel). 2022. PMID: 36145272 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources